» Articles » PMID: 27560277

Rate Control in Atrial Fibrillation

Overview
Journal Lancet
Publisher Elsevier
Specialty General Medicine
Date 2016 Aug 26
PMID 27560277
Citations 50
Authors
Affiliations
Soon will be listed here.
Abstract

Control of the heart rate (rate control) is central to atrial fibrillation management, even for patients who ultimately require control of the rhythm. We review heart rate control in patients with atrial fibrillation, including the rationale for the intervention, patient selection, and the treatments available. The choice of rate control depends on the symptoms and clinical characteristics of the patient, but for all patients with atrial fibrillation, rate control is part of the management. Choice of drugs is patient-dependent. β blockers, alone or in combination with digoxin, or non-dihydropyridine calcium-channel blockers (not in heart failure) effectively lower the heart rate. Digoxin is least effective, but a reasonable choice for physically inactive patients aged 80 years or older, in whom other treatments are ineffective or are contraindicated, and as an additional drug to other rate-controlling drugs, especially in heart failure when instituted cautiously. Atrioventricular node ablation with pacemaker insertion for rate control should be used as an approach of last resort but is also an option early in the management of patients with atrial fibrillation treated with cardiac resynchronisation therapy. However, catheter ablation of atrial fibrillation should be considered before atrioventricular node ablation. Although rate control is a top priority and one of the first management issues for all patients with atrial fibrillation, many issues remain.

Citing Articles

Calcium channel blocker use and outcomes following transcatheter aortic valve intervention for aortic stenosis.

Miyahara D, Izumo M, Sato Y, Shoji T, Yamaga M, Sekiguchi M Cardiovasc Interv Ther. 2025; 40(2):352-361.

PMID: 39899262 DOI: 10.1007/s12928-025-01094-w.


Reassessing Ivabradine: Potential Benefits and Risks in Atrial Fibrillation Therapy.

Alijanzadeh D, Moghim S, Zarand P, Akbarzadeh M, Zarinfar Y, Khaheshi I Cardiovasc Drugs Ther. 2024; .

PMID: 39656365 DOI: 10.1007/s10557-024-07652-3.


Ablation Compared to Pharmacological Treatment for the Reduction of Atrial Fibrillation Recurrence: A Meta-Analysis.

Kaye A, Jones N, Tran T, Khaled M, Tilmon S, Lieu M Cureus. 2024; 16(6):e62728.

PMID: 39036176 PMC: 11259506. DOI: 10.7759/cureus.62728.


Atrial fibrillation: better symptom control with rate and rhythm management.

Gupta D, Rienstra M, Van Gelder I, Fauchier L Lancet Reg Health Eur. 2024; 37:100801.

PMID: 38362560 PMC: 10866934. DOI: 10.1016/j.lanepe.2023.100801.


New Insights into Rate Control: Time in Target Range of Resting Heart Rate and Major Adverse Outcomes in Atrial Fibrillation.

Lai Y, Xu X, Zhang S, Huang R, Huang Y, Zhong X Glob Heart. 2024; 19(1):3.

PMID: 38222098 PMC: 10786089. DOI: 10.5334/gh.1251.